Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27853162)
Watch
English
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.
scientific article
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
25939061
retrieved
13 November 2016
title
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.
(English)
1 reference
stated in
PubMed
PubMed ID
25939061
retrieved
13 November 2016
main subject
non-small-cell lung carcinoma
1 reference
based on heuristic
inferred from title
author
Enriqueta Felip
object named as
Enriqueta Felip
series ordinal
3
0 references
Byoung Chul Cho
object named as
Byoung Chul Cho
series ordinal
4
0 references
Pasi A Jänne
series ordinal
15
object named as
Pasi A Jänne
0 references
Ana Vivancos
object named as
Ana Vivancos
series ordinal
9
1 reference
stated in
ORCID Public Data File 2021
author name string
Kenneth S Thress
series ordinal
1
0 references
Cloud P Paweletz
series ordinal
2
0 references
Daniel Stetson
series ordinal
5
0 references
Brian Dougherty
series ordinal
6
0 references
Zhongwu Lai
series ordinal
7
0 references
Aleksandra Markovets
series ordinal
8
0 references
Yanan Kuang
series ordinal
10
0 references
Dalia Ercan
series ordinal
11
0 references
Sarah E Matthews
series ordinal
12
0 references
Mireille Cantarini
series ordinal
13
0 references
J Carl Barrett
series ordinal
14
0 references
Geoffrey R Oxnard
series ordinal
16
0 references
language of work or name
English
0 references
publication date
June 2015
0 references
published in
Nature Medicine
0 references
volume
21
0 references
page(s)
560-2
0 references
issue
6
0 references
cites work
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
20 March 2017
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
20 March 2017
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
20 March 2017
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
20 March 2017
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
20 March 2017
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
20 March 2017
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
20 March 2017
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
20 March 2017
Screening for epidermal growth factor receptor mutations in lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
7 April 2017
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
29 September 2017
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
29 September 2017
Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
29 September 2017
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
29 September 2017
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4771182
retrieved
29 September 2017
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FNM.3854
retrieved
21 January 2018
Identifiers
DOI
10.1038/NM.3854
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
8360
Dimensions Publication ID
1005299046
0 references
OpenCitations bibliographic resource ID
8360
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
8360
PMCID
4771182
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
8360
PubMed ID
25939061
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
8360
Springer Nature article ID
10.1038/nm.3854
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
